With headquarters in Montréal, Canada, Paladin Labs Inc. is a leading specialty pharmaceutical company focused on acquiring or licensing emerging pharmaceuticals for the Canadian market.
Their dedicated sales and marketing organization has propelled Paladin to become one of Canada’s pioneers in specialty pharmaceuticals.
Paladin is an operating company of Endo International plc (NASDAQ: ENDP), a highly focused generics and specialty branded pharmaceutical company delivering quality medicines to patients through excellence in development, manufacturing and commercialization.
Paladin Labs Inc. Announces Launch of New Indication for XIAFLEX® (Collagenase Clostridium Histolyticum), Broadening Its Use to the Treatment of Appropriate Patients with Peyronie's Disease
For complete list of press releases click Here.